RecruitingEarly Phase 1NCT06693960

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach


Sponsor

Washington State University

Enrollment

16 participants

Start Date

Sep 26, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.


Eligibility

Min Age: 18 YearsMax Age: 64 Years

Inclusion Criteria9

  • Between 18-64 years old and healthy
  • Not taking any medications (prescription and non-prescription) or dietary/herbal supplements that can interfere with study drug pharmacokinetics
  • Willing to abstain from consuming dietary/herbal supplements and citrus juices for several weeks
  • Willing to abstain from cannabis/marijuana, hemp, and THC- and CBD-containing products for several weeks
  • Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and the morning of the first day of each study arm
  • Willing to abstain from consuming any alcoholic beverages for at least 1 day prior to any study day and during the study day
  • Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms). Specifically, regardless of the use hormonal-based birth control, a non-hormonal method should be used for the duration of the study and for three weeks following cessation of participation.
  • Willing to abstain from consuming oregano (as a food additive or otherwise) for the duration of the study
  • Geographically located within a 40-mile radius of Spokane and have the time to participate

Exclusion Criteria10

  • Under 18 or over 64 years old
  • Taking medications or dietary/herbal supplements that can interfere with study drug pharmacokinetics
  • Have a major illness
  • Taking medication/supplements for a mineral deficiency
  • History of intolerance or allergy to oregano or any of the cocktail drugs (caffeine, dextromethorphan, losartan, midazolam, and omeprazole)
  • Use of cannabis/marijuana, hemp, and CBD- and/or THC-containing products within the last month
  • Currently using drugs or illicit substances for recreational purposes
  • Pregnant or nursing
  • Geographically located outside the 40-mile radius of Spokane and do not have the time to participate
  • Cannot read and speak English

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTOregano

Oil of oregano administered as a softgel (180 mg).

DRUGDrug cocktail

Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).


Locations(1)

Washington State University College of Pharmacy and Pharmaceutical Sciences

Spokane, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06693960


Related Trials